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ABSTRACT
AQ2
Since 1997, studies have found that Asians need lower clozapine doses than Caucasians. Caucasians with average clozapine 
metabolism may need from 300 to 600 mg/day to reach the therapeutic range (350 ng/ml). Thus, serum clozapine 
concentration-to-dose (C/D) ratios typically range between 0.60 (male smokers) and 1.20 (female non-smokers). A 2019 
systematic review of clozapine levels demonstrated weighted mean C/D ratios of 1.57 in 876 East Asians and 1.07 in 1147 
Caucasians (P <.001). In Asian countries, average clozapine doses are lower than 300 mg/day. After sex and smoking 
stratification in 5 Asian samples with clozapine concentrations, the clozapine dose required to reach 350 ng/ml in female 
non-smokers ranged from 145 to 189 mg/day and in male smokers, from 259 to 294 mg/day. Thus, in Asian patients with 
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This review article proposes that the clozapine package 
insert (or drug labeling) and psychiatric literature 
should inform physicians that Asian patients with 
average clozapine metabolism are likely to need between 
150 and 300 mg/day of clozapine to reach therapeutic 
concentrations, in contrast with Caucasian patients 
with average clozapine metabolism who need 300 to 
600 mg/day.
WHAT IS THE EVIDENCE?
A reader familiar with United States psychiatric 
textbooks[1] or review articles[2] or British textbooks[3] 
or guidelines[4] may find the title of this article 
surprising. A British textbook[3] states, “The range 
[for clozapine dosing] is approximately 250 mg/day 
(female non-smoker) to 550 mg/day (male smoker)” 
and makes no reference to Asian patients.
Average response in randomized clinical trials (RCTs) 
is used by pharmaceutical companies to provide 
recommended average doses, but this approach is 
misguided when statistical heterogeneity is present and 
when the mean does not represent the heterogeneous 
sample well.[5] As a matter of fact, the question asked 
in a Cochrane review, “What is the optimal dose for 
AQ1 clozapine in schizophrenia?”[6] is an irrelevant question 
because there is no average clozapine dose that is “best”. 
The right dose depends on the clozapine clearance of 
the individual patient, which is mainly mediated by 
CYP1A2 and is significantly influenced by ethnicity, 
smoking status and sex, all of which have major 
influence on CYP1A2 activity.[7] A better question 
therefore is to ask what dose is optimal for specific 
sub-groups: 1) Asian non-smoker females, 2) Asian 
non-smoker males, 3) Asian smoker females, 4) Asian 
smoker males, 5) non-Asian non-smoker females, 
6) non-Asian non-smoker males, 7) non-Asian smoker 
females, and 8) non-Asian smoker males.[8]
These questions are at the heart of clinical practice but 
were not asked when clozapine was introduced in the 
market. Traditionally, drug studies for approval focused 
on Caucasian subjects, predominantly male, but this 
state of affairs is no longer satisfactory. The current 
need is to understand how different racial and ethnic 
ancestry can lead to differences in efficacy and safety 
in the use of various drugs.
WHO ARE ASIANS?
According to the Food and Drug Administration (FDA), 
the Asian phenotype includes people whose ancestral 
origins range geographically from Pakistan to Japan.[9] 
Within that group is a more homogeneous genetic group 
called East Asians, who comprise of Chinese, Korean, 
Japanese, and Mongolian people. This classification is 
largely driven by the history of genetic evolution.[10] 
This means that people from Western Asia[11] are 
genetically different from other Asians and are closer to 
Caucasian Europeans;[10] it also means that the original 
people from the Americas[10] have actually descended 
from East Asians and are likely to be genetically close 
to East Asians. In this review, we report clozapine levels 
from Vellore, which probably reflects a population from 
Southern India, while the Northern India population 
probably includes a more complex mix.[12]
average metabolism (with no inducers other than smoking, with no inhibitors, and in the absence of extreme obesity), the 
dose needed for clinical response may range between 150 mg/day for female non-smokers to 300 mg/day for male smokers. 
Clozapine levels may help personalize dosing in clozapine poor metabolizers (PMs) and ultrarapid metabolizers (UMs). 
Asian PMs may need very low doses (50-150 mg/day) to obtain therapeutic concentrations. About 10% (range 2-13%) of 
Asians are genetic PM cases. Other PMs are patients taking CYP1A2 inhibitors such as fluvoxamine, oral contraceptives, 
and valproate. Temporary clozapine PM status may occur during severe systemic infections/inflammations with fever 
and C-reactive protein (CRP) elevations. Asian UMs include patients taking potent inducers such as carbamazepine or 
phenytoin, and rarely, valproate.
Key words: Asian continental ancestry group/genetics, blood, CYP1A2, clozapine, drug labeling, India, pharmacokinetics, 
sex, smoking
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THE EVIDENCE FROM CLOZAPINE 
BLOOD LEVELS
Although clozapine prescribers in Western countries 
are not aware that Asians need lower clozapine doses, 
this is not a new concept. In 1997, Chang et al.[13] and 
Chong et al.[14] showed that Chinese patients who used 
half the clozapine dosage had concentrations similar 
to Caucasians. Moreover, in 2005, Ng et al.[15] found 
that 20 Singaporean Asians (from 3 ethnic groups: 
Chinese, Indian, and Malay) had higher clozapine 
concentration-to-dose (C/D) ratios than 20 Australian 
Caucasians.
The clozapine C/D ratio is a measure of clozapine drug 
clearance, which can be influenced by genetic, personal, 
and environmental factors.[16] The clozapine C/D ratio 
can be used to distinguish patients based on clozapine 
metabolism. Thus, patients with a very low clozapine 
C/D ratio belong to an ultrarapid metabolizer (UM) 
phenotype, while those with a very high C/D ratio 
belong to a poor metabolizer (PM) phenotype. In 2015, 
a review[16] proposed that in US schizophrenia patients, 
Caucasians with average clozapine metabolism usually 
need 300-600 mg/day to reach the lowest part of the 
therapeutic range (350 ng/ml). US male smokers usually 
reach a therapeutic concentration of ≥350 ng/ml with a 
dosage of 600 mg/day; this corresponds to a C/D ratio 
of 0.58 (350/600). US female non-smokers usually 
reach a concentration of ≥350 ng/ml with a dosage 
of only 300 mg/day. This corresponds to a C/D ratio 
of 1.17 (350/300). Therefore in the US, clozapine 
C/D ratios typically range between approximately 
0.60 and 1.20.[16]
Based on the limited published data on Chinese 
patients,[13-15] and the fact that clozapine follows linear 
kinetics, the review16 also proposed that East Asians 
may have clozapine C/D ratios that are twice as high, 
ranging from 1.20 to 2.40, which means that they need 
only half the clozapine dosage of US Caucasians.[16] In 
2019, a systematic review of clozapine levels supported 
that conclusion,[8] since the clozapine C/D ratio was 
higher when comparing weighted mean values of 
1.57 in 876 East Asians and 1.07 in 1147 Caucasians 
(P < 0.001). Interestingly, a Mexican study[17] which 
provided no information on patient ethnicity described 
clozapine C/D ratios similar to East Asians.
THE EVIDENCE FROM CLOZAPINE 
DOSING IN ASIAN COUNTRIES
In 1998, Farooq[18] reported his clinical observation that 
Pakistani psychiatrists also used lower doses similar 
to those used by Chinese psychiatrists, and proposed 
that Pakistanis also have lower clozapine clearance 
than Caucasians, but similar to Chinese. However, 
these comments on the need for low clozapine doses 
in Chinese and Pakistani patients were largely ignored 
in Western countries.
Clozapine is widely used in China. In 2012, Wang and 
Li[19] stated that the mean dose reported in Chinese 
studies was 216 mg/day, which was much lower than 
the 431 mg/day reported in the non-Chinese literature. 
A dosing study with >3,000 samples from the 
Japanese clozapine database described a mean dose of 
186 mg/day.[20] In a survey of 117 Indian psychiatrists, 
Shrivastava and Shah[21] indicated that almost all (86%) 
of their patients were stabilized on clozapine doses 
lower than 300 mg/day. A recent Asian review described 
clozapine daily dosing in single samples from several 
different countries. In countries with no published 
blood levels, the sample average doses (in mg/day) were 
368 in Sri Lanka, 364 in Malaysia, 245 in Thailand, 
193 in Myanmar, 182 in Vietnam, 158 in Pakistan, 142 
in Bangladesh and 58 in Indonesia.[22]
DOSING RECOMMENDATION FOR 
ASIANS IN THE ABSENCE OF BLOOD 
LEVELS
If the psychiatrist has access to blood levels, the best 
way to personalize clozapine dosing[23] is to use a 
dose that provides a trough steady-state clozapine 
concentration of at least 350 ng/ml.[24] Alternatively, 
the data from the five Asian samples[25] after sex and 
smoking stratification can be used to orient Asian 
clinicians who have no access to an assessment of blood 
levels. The five samples were from Beijing,[8,26] Taipei,[27] 
Seoul,[28] and Vellore.[29] In these 5 Asian samples, the 
clozapine dose required to reach at least 350 ng/ml in 
female non-smokers ranged from 145 to 189 mg/day 
and in male smokers, from 259 to 294 mg/day.
These clozapine dosing guidelines are based on 
patients with average metabolism who are not using 
inducers (other than smoking) or inhibitors and do 
not have extreme obesity. The dose needed for clinical 
response in Asian patients with average clozapine 
metabolism ranges between 150 mg/day for female 
non-smokers and 300 mg/day for male smokers. After 
reaching these doses, when a psychiatrist is faced 
with the need to ascertain whether the patient is not 
going to respond to clozapine, they may want to reach 
at least 200 mg/day in an Asian female non-smoker 
before declaring her to be non-responsive; likewise, an 
Asian male smoker will need at least 350 mg/day. Asian 
female smokers and Asian non-smoking males will need 
intermediate doses.
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THE IMPORTANCE OF USING CLOZAPINE 
BLOOD LEVELS IN ASIANS
This review has so far focused on Asian non-smoking 
females or Asian smoking males with average 
metabolism, but not all patients are average for 
clozapine metabolism. Clozapine PMs and UMs exist, 
and they can be genetic or non-genetic PMs or UMs.
In the 5 Asian samples,[25] approximately 10% (range 
2-13%) of possible genetic clozapine PMs needed very 
low clozapine doses of approximately 50-125 mg/day to 
reach 350 ng/ml. In Vellore, the PM percentage appeared 
to be 2%. Moreover, phenoconversion by environmental 
and personal variables can make a normal clozapine 
metabolizer appear to be a phenotypical clozapine 
PM. Fluvoxamine is an extremely powerful inhibitor of 
clozapine metabolism that makes most patients resemble 
clozapine PMs,[30] and should never be co-prescribed 
with clozapine in the absence of access to blood levels. 
Other powerful inhibitors of clozapine metabolism 
that are likely to make a patient a clozapine PM are: 
ciprofloxacin, oral contraceptives, and high doses of 
caffeine. Phenothiazines, tricyclic antidepressants, and 
high doses of sertraline can also phenoconvert patients 
to clozapine PM.[30] Valproic acid in some patients may 
also inhibit clozapine metabolism.[29,31]
More importantly, using the clozapine C/D ratio in 
the Vellore sample, we estimated that a clozapine PM 
male smoker who was taking valproic acid would only 
need 105 mg/day to get therapeutic concentrations.[25]
Clozapine deposits in fat tissue,[32] and this decreases 
clozapine clearance. After combining four Asian samples 
with measures of weights, we found that 1.1% (5/429) 
of patients appear to be phenotypic clozapine PMs due 
to extreme obesity.[25]
The most common cause of clozapine phenotypic PM 
status may be a severe infection or severe inflammation 
with systemic manifestations that include fever and/or 
elevations of C-reactive protein (CRP). The inflammation 
releases cytokines that inhibit CYP1A2 and other CYPs, 
thereby increasing clozapine levels.[33] Most clinicians 
are not aware that pneumonia can be lethal in clozapine 
patients because it can lead to clozapine intoxication.[34] 
Halving the clozapine dose when pneumonia is diagnosed, 
or when any serious inflammation/infection with fever 
and/or CRP elevation occurs, may avoid the development 
of clozapine intoxication.[33,34] The complexities involved 
in diagnosing fever in clozapine patients are reviewed in 
a recent article.[35]
Patients taking a potent inducer such as rifampicin 
or one of the three potent antiepileptic inducers, 
phenytoin or phenobarbital, can become clozapine 
UMs and require much higher clozapine doses.[30] 
Valproic acid, instead of being an inhibitor of clozapine 
metabolism, can be an inducer in some patients. Studies 
suggest that when valproic acid acts as an inducer, it 
mainly induces norclozapine metabolism[31,36-38] but can 
sometimes contribute to the patient becoming a UM 
who needs very high clozapine doses.[39] Norclozapine 
is clozapine’s main metabolite and has no antipsychotic 
efficacy but may contribute to adverse drug reactions.[40] 
In summary, in some clozapine patients, valproic acid 
can act as an inhibitor of clozapine metabolism and 
in others, as an inducer, particularly of norclozapine 
metabolism.[41] During early titrations, it is important 
to consider the risk of inhibition.
Mild CYP1A2 inducers are omeprazole and intake 
of cruciferous vegetables such as broccoli. These 
latter compounds and the polycyclic aromatic 
hydrocarbons (PAH) found in the smoke of tobacco 
bind to the aryl hydrocarbon receptor (AhR), inducing 
CYP1A2 expression.[42] The same PAH in barbecued 
food can act as it does in tobacco smoke, but one would 
have to consume great quantities of barbecued food to 
gain the same effect as daily smoking. More importantly, 
in people from India or Sri Lanka,[43] high coffee 
intake has been associated with induction of CYP1A2 
expression, possibly because of the way the coffee 
beans are roasted. Using the clozapine C/D ratio in the 
Vellore sample, we estimated that a particular clozapine 
UM would need 1029 mg/day of clozapine to reach a 
clozapine level of 350 ng/ml. She was a non-smoking 
female who reported consuming 10 cups of coffee/day, 
much higher than other patients. Assuming that her 
single clozapine level was not contaminated by lack 
of adherence, she appeared to be a clozapine UM 
explained by the high induction produced by the 
roasting of coffee beans.[25]
In conclusion, the best way of personalizing dosing 
for clozapine PMs and UMs, whether genetic or 
non-genetic by source, is to measure clozapine blood 
levels.[23]
THE NEED FOR STARTING WITH LOWER 
DOSES AND SLOWER TITRATION IN 
ASIAN PATIENTS
Asian patients need half the dose to which Caucasian 
patients are usually up-titrated. Therefore to prevent 
myocarditis, in Asians, it may be desirable to start with 
12.5 mg/day and, if tolerated, to reach 50 mg/day at day 
7, 100 mg/day at day 14, and 150 mg/day at day 21. 
Then, after reaching a steady-state (five days later), a 
trough clozapine level could be obtained to personalize 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
Leon, et al.: Clozapine in Asians
Indian Journal of Psychological Medicine | Volume XX | Issue XX | Month 2019 5
dosing. It is preferable to require a normal CRP level for 
starting clozapine, or else systemic inflammation-related 
reduction in clozapine metabolism may compromise 
the safety of the titration.[23,44] Weekly CRP can be 
measured with the white blood count (WBC). If the 
CRP is elevated, clozapine should be stopped until the 
CRP normalizes because this may be an initial sign of 
clozapine-induced inflammation that can progress to 
myocarditis.[23,44] Frequently, clozapine up-titration is 
conducted in the background of a prior antipsychotic, 
and so delaying clozapine titration until CRP 
normalizes is safe. If the patient is not already taking 
another antipsychotic, an additional antipsychotic can 
be given until it is determined that the patient can 
tolerate a slower clozapine up-titration.
Two articles have independently proposed that 
clozapine-induced myocarditis is a hypersensitive 
reaction similar to lamotrigine-induced Stevens-Johnson 
syndrome that is produced by rapid up-titration.[45,46] 
Normal titration may lead to myocarditis in clozapine 
PMs, such as those taking valproic acid.[47] If the 
clozapine up-titration is too fast for a specific patient, 
a clozapine-induced inflammation will develop, 
manifested as CRP elevation. This will further reduce 
clozapine metabolism and predispose to myocarditis. 
The high incidence of clozapine-induced myocarditis in 
Australia may be partly explained by the use of 
Caucasian-level titration in patients of Asian ancestry, 
considering the increase in Asian emigration to Australia 
in the last ten years.[8]
INTERPRETING CLOZAPINE BLOOD 
LEVELS
Clinicians frequently fail to understand that a single 
clozapine level must be viewed with caution and that a 
pattern change across several levels is easier to interpret. 
Laboratory, technical, and natural variations can cause 
some day-to-day variations in clozapine levels, even 
after assuming the stability of all possible confounding 
factors such as trough (early morning before medication 
intake) and steady-state levels (≥5 days with no 
clozapine dose change), drug interactions, smoking, 
and caffeine intake.[48] The most important changes 
in clozapine levels in outpatients are due to a lack of 
compliance.[49] Based on an RCT in an inpatient setting 
with very strict control over compliance and many levels 
every other week for months,[50] we have suggested that 
only a change by a factor of 2 is probably meaningful 
from the clinician’s perspective. This means that if 
an individual has a clozapine level of 500 ng/ml, the 
next one under the same stable conditions should not 
be >1000 or <250 ng/ml. However, a change from 
500 to 400 ng/ml is probably not significant.[48]
CONCLUSION
This review article proposes that Asians, defined as 
people whose ancestral origins range geographically 
from Pakistan to Japan, and who comprise up to 50% 
of the world’s population, may need half the clozapine 
dosage used in Western countries. Psychiatrists in 
India, and more widely, in Asia, need to be aware that 
the clozapine doses needed by Asian patients are half 
those needed by Caucasian patients.
Based on the evidence presented in this article, Asian 
psychiatrists should encourage their hospitals and 
facilities, where possible, to developing laboratories 
that can allow obtaining clozapine levels to become 
routine practice. This would help personalize clozapine 
dosing. Asian pharmaceutical companies should 
consider developing clozapine formulations that allow 
lower doses, such as 12.5, 10, or even 5 mg. These low 
doses are far more appropriate for starting clozapine 
in Asian patients. This article estimates dosing for 
Asians based on linear kinetics and the estimation 
that the lower therapeutic range is 350 ng/ml, but this 
value is mainly based on studies in Caucasians and 
response-plasma levels in Asians are needed. Future 
studies in Asian patients need to establish whether 
or not this value (350 ng/ml) needs to be modified in 
Asians.
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